Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5

Science

Volumn 306, Issue 5695, 2004, Pages 485-487

  Lederman, Michael M ^a   Veazey, Ronald S ^b   Offord, Robin ^c   Mosier, Donald E ^d   Dufour, Jason ^b   Mefford, Megan ^b   Piatak Jr , Michael ^e   Lifson, Jeffrey D ^e   Salkowitz, Janelle R ^a   Rodriguez, Benigno ^a   Blauvelt, Andrew ^f,g   Hartley, Oliver ^c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e SAIC FREDERICK INC   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE CONTROL; DISEASES; HUMAN ENGINEERING; IMMUNOLOGY; MICROBIOLOGY;

CHEMOKINE RECEPTORS; HUMAN IMMUNO-DEFICIENCY VIRUS (HIV); MICROBICIDES;

VIRUSES;

CHEMOKINE RECEPTOR CCR5; RANTES;

BIOLOGY;

ADSORPTION; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SEXUAL TRANSMISSION; SIMIAN IMMUNODEFICIENCY VIRUS; VAGINA MUCOSA; VAGINITIS; VIRUS TRANSMISSION;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; HIV INFECTIONS; HIV-1; MACACA MULATTA; RANTES; RECEPTORS, CCR5; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VAGINA;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; MACACA; MACACA MULATTA; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 5644247983     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1099288     Document Type: Article

References (35)

1. R. Liu et al., Cell 86, 367 (1996).
2. P. A. Zimmerman et al., Mol. Med. 3, 23 (1997).
3. Y. Huang et al., Nature Med. 2, 1240 (1996).
4. M. Dean et al., Science 273, 1856 (1996).
5. J. R. Salkowitz et al., Clin. Immunol. 98, 200 (2001).
6. E. A. Berger, P. M. Murphy, J. M. Farber, Annu. Rev. Immunol. 17, 657 (1999).
7. P. R. Clapham, A. McKnight, J. Cen. Virol. 83, 1809 (2002).
8. T. B. Geijtenbeek et al., Cell 100, 587 (2000).
9. S. C. Turville et al., Blood 98, 2482 (2001).
10. L. Wu et al., Proc. Natl. Acad. Sci. U.S.A. 99, 1568 (2002).
11. C. J. Miller, R. J. Shattock, Microbes Infect. 5, 59 (2003).
12. M. Pope, A. T. Haase, Nature Med. 9, 847 (2003).
13. C. W. Davis, R. W. Doms, J. Exp. Med. 199, 1037 (2004).
14. G. Simmons et al., Science 276, 276 (1997).
15. D. E. Mosier et al., J. Virol. 73, 3544 (1999).
16. T. Kawamura et al., J. Exp. Med. 192, 1491 (2000).
17. V. S. Torre et al., J. Virol. 74, 4868 (2000).
18. R. Sabbeef et al., J. Virol. 75, 661 (2001).
19. O. Hartley et al., J. Virol. 77, 6637 (2003).
20. T. Kawamura et al., Proc. Natl. Acad. Sci. U.S.A. 100, 8401 (2003).
21. D. Mosier, unpublished data.
22. A. Amara et al., J. Exp. Med. 186, 139 (1997).
23. I. Aramori et al., EMBO J. 16, 4606 (1997).
24. C. Alkhatib, M. Locati, P. E. Kennedy, P. M. Murphy, E. A. Berger, Virology 234, 340 (1997).
25. M. Mack et al., J. Exp. Med. 187, 1215 (1998).
26. C. Pastore et al., Antimicrob. Agents Chemother. 47, 509 (2003).
27. Materials and methods are available on Science Online.
28. R. Veazey, unpublished data.
29. J. D. Lifson et al., J. Virol. 75, 10187 (2001).
30. O. Hartley, unpublished data.
31. R. S. Veazey et al., Nature Med. 9, 343 (2003).
32. R. S. Veazey et al., J. Exp. Med. 198, 1551 (2003).
33. C. C. Tsai et al., AIDS Res. Hum. Retroviruses 20, 11 (2004).
34. R. H. Gray et al., Lancet 357, 1149 (2001).
35. This work was supported by grants from the NIH (Al 51649 and Al 36219) and from the AIDS Section, Swiss National Science Foundation and was supported in part with U.S. federal funds from the National Cancer Institute, NIH, under contract N01-CO-124000 to J.D.L and M.P.). We thank S. Cairns, R. Black, J. Kagan, and J. Turpin (National Institute of Allergy and Infectious Diseases) for their support and advice; M. Robertson for administrative assistance; F. Blobel and A. Kung (Gryphon Therapeutics) for provision of PSC-RANTES, and J. Leblanc, K. Medvik, W. Mackay, and M. Dodd for technical assistance. R.E.O. is a cofounder of Gryphon Therapeutics, which focuses on therapeutic applications of synthetic proteins. He both holds equity in the company and is a paid consultant.